ERBB2 and neoplasm: In the MINDACT trial, MammaPrint® reclassified 46% of patients with a high clinical risk to low genomic risk in sHR-positive/HER2-negative tumours, resulting in a 5-year disease-free survival rate of 90.3% without chemotherapy, compared with 85.7% in the high genomic risk group [19].